BTYNB
规格
| Cas Number | 304456-62-0 |
| 规格或纯度 | ≥96% |
| 纯度 | ≥96% |
| 包装 | 100mg 或 25mg 或 500mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 62 mg/mL (200.53 mM); Ethanol: 4 mg/mL (12.93 mM); Water: Insoluble; |
| 简短描述 | NF-κB 抑制剂 |
| 英文简短描述 | NF-κB Inhibitors |
| 过滤标签 | Apoptosis,c-Myc |
| 储存温度 | 避光,-20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | BTYNB（BTYNB IMP1 抑制剂，MDK6620）是 IMP1 与 c-Myc mRNA 结合的强效选择性抑制剂。BTYNB 能下调 β-TrCP1 mRNA 并减少核转录因子-kappa B（NF-κB）的激活。BTYNB 通过损害 IGF2 mRNA 结合蛋白 1（IGF2BP1）与 RNA 的结合，破坏了这种增强子功能。 |
| 英文描述 |
Information BTYNB BTYNB (BTYNB IMP1 Inhibitor, MDK6620) is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA. BTYNB downregulates β-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-κB) . BTYNB disrupts this enhancer function by impairing IGF2 mRNA-binding protein 1 (IGF2BP1)-RNA association. Targets IMP1 ; c-Myc ; NF-κB In vitro In cells, BTYNB downregulates several mRNA transcripts regulated by IMP1. BTYNB destabilizes c-Myc mRNA, resulting in downregulation of c-Myc mRNA and protein. BTYNB downregulates β-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-κB). The oncogenic translation regulator, eEF2, emerges as a new IMP1 target mRNA, enabling BTYNB to inhibit tumor cell protein synthesis. BTYNB potently inhibits proliferation of IMP1-containing ovarian cancer and melanoma cells with no effect in IMP1-negative cells. Overexpression of IMP1 reverses BTYNB inhibition of cell proliferation. BTYNB completely blocks anchorage-independent growth of melanoma and ovarian cancer cells in colony formation assays. Cell Research(from reference) Cell lines：SK-MEL2 cells Concentrations：10 μM Incubation Time：24 h |